| dc.contributor.author | Erden, İlker | |
| dc.contributor.author | Uçak, Haydar | |
| dc.contributor.author | Demir, Betül | |
| dc.contributor.author | Çicek, Demet Bakar | |
| dc.contributor.author | Dertlioğlu, Selma | |
| dc.contributor.author | Öztürk, Savaş | |
| dc.contributor.author | Aydın, Süleyman | |
| dc.date.accessioned | 2019-10-17T07:35:10Z | |
| dc.date.available | 2019-10-17T07:35:10Z | |
| dc.date.issued | 2015 | en_US |
| dc.identifier.issn | 1952-4013 | |
| dc.identifier.issn | 1167-1122 | |
| dc.identifier.uri | https://doi.org/10.1684/ejd.2015.2575 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12462/7646 | |
| dc.description | Öztürk, Savaş (Balikesir Author) | en_US |
| dc.description.abstract | Salusin is a bioactive peptide, discovered by Shichri et al.[1] in 2003. This multifunctional bioactive peptide is present in blood, urine and tissues in two forms: salusin-α and salusin-β. Salusins have important effects on the cardiovascular system. In particular, salusin-β is the most potent hypotensive peptide and has a vasodilator effect. This peptide induces hypotension, bradycardia and cardiac dysfunction through a cholinergic mechanism. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | John Libbey Eurotext Ltd | en_US |
| dc.relation.isversionof | 10.1684/ejd.2015.2575 | en_US |
| dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
| dc.subject | Atherosclerosis | en_US |
| dc.title | Serum salusin-alpha and salusin-beta levels in patients with psoriasis | en_US |
| dc.type | other | en_US |
| dc.relation.journal | European Journal of Dermatology | en_US |
| dc.contributor.department | Tıp Fakültesi | en_US |
| dc.contributor.authorID | 0000-0001-8405-7730 | en_US |
| dc.contributor.authorID | 0000-0002-6190-5124 | en_US |
| dc.identifier.volume | 25 | en_US |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.startpage | 352 | en_US |
| dc.identifier.endpage | 353 | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
